Royalty Pharma (RPRX) Competitors $32.82 +0.11 (+0.34%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RPRX vs. ZTS, CORT, JAZZ, PRGO, SUPN, PCRX, OMER, NKTR, ASMB, and CPIXShould you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Zoetis (ZTS), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry. Royalty Pharma vs. Zoetis Corcept Therapeutics Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Omeros Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Zoetis (NYSE:ZTS) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment. Do institutionals & insiders have more ownership in ZTS or RPRX? 92.8% of Zoetis shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, ZTS or RPRX? Zoetis has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Do analysts prefer ZTS or RPRX? Zoetis currently has a consensus price target of $214.40, indicating a potential upside of 36.87%. Royalty Pharma has a consensus price target of $42.50, indicating a potential upside of 29.49%. Given Zoetis' stronger consensus rating and higher possible upside, equities analysts clearly believe Zoetis is more favorable than Royalty Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zoetis 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08Royalty Pharma 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ZTS or RPRX more profitable? Royalty Pharma has a net margin of 37.94% compared to Zoetis' net margin of 26.86%. Zoetis' return on equity of 53.82% beat Royalty Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Zoetis26.86% 53.82% 18.86% Royalty Pharma 37.94%24.40%14.01% Is ZTS or RPRX a better dividend stock? Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.3%. Royalty Pharma pays an annual dividend of $0.88 per share and has a dividend yield of 2.7%. Zoetis pays out 36.6% of its earnings in the form of a dividend. Royalty Pharma pays out 60.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 14 consecutive years. Does the MarketBeat Community believe in ZTS or RPRX? Zoetis received 591 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 77.96% of users gave Zoetis an outperform vote while only 67.99% of users gave Royalty Pharma an outperform vote. CompanyUnderperformOutperformZoetisOutperform Votes91677.96% Underperform Votes25922.04% Royalty PharmaOutperform Votes32567.99% Underperform Votes15332.01% Which has stronger earnings and valuation, ZTS or RPRX? Zoetis has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZoetis$9.26B7.55$2.49B$5.4728.64Royalty Pharma$2.26B8.36$858.98M$1.4522.63 Does the media favor ZTS or RPRX? In the previous week, Zoetis had 32 more articles in the media than Royalty Pharma. MarketBeat recorded 45 mentions for Zoetis and 13 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.28 beat Zoetis' score of 1.10 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 32 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryZoetis beats Royalty Pharma on 17 of the 22 factors compared between the two stocks. Get Royalty Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPRX vs. The Competition Export to ExcelMetricRoyalty PharmaPharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$18.92B$6.89B$11.13B$7.82BDividend Yield2.73%3.06%5.61%4.22%P/E Ratio22.637.4422.0018.48Price / Sales8.36242.6626.02103.91Price / Cash7.9465.8517.6234.62Price / Book1.836.512.664.25Net Income$858.98M$143.21M$1.03B$248.23M7 Day Performance3.57%3.97%1.27%3.29%1 Month Performance4.62%0.37%-0.74%2.43%1 Year Performance18.48%2.59%536.03%5.54% Royalty Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPRXRoyalty Pharma4.3415 of 5 stars$32.82+0.3%$42.50+29.5%+16.3%$18.92B$2.26B22.6380Positive NewsZTSZoetis4.5117 of 5 stars$146.85-0.9%$214.40+46.0%-2.7%$65.52B$9.26B26.8513,800Upcoming EarningsOptions VolumePositive NewsCORTCorcept Therapeutics4.821 of 5 stars$62.90+1.1%$143.25+127.7%+213.4%$6.64B$675.04M49.92300Upcoming EarningsShort Interest ↓Positive NewsJAZZJazz Pharmaceuticals4.8379 of 5 stars$100.34-2.4%$187.71+87.1%+4.7%$6.09B$4.07B14.133,200Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsPRGOPerrigo4.8592 of 5 stars$24.41-3.6%$33.00+35.2%-21.9%$3.33B$4.37B-20.868,900Upcoming EarningsDividend AnnouncementShort Interest ↑Positive NewsSUPNSupernus Pharmaceuticals3.1437 of 5 stars$30.29-1.5%$36.00+18.9%+6.2%$1.69B$661.82M28.31580Upcoming EarningsPCRXPacira BioSciences1.9282 of 5 stars$25.90+5.1%$26.67+3.0%+3.6%$1.20B$700.97M-12.76720Upcoming EarningsNews CoverageOMEROmeros3.8273 of 5 stars$6.70-1.2%$22.50+235.8%+130.4%$389.03MN/A-2.90210Positive NewsNKTRNektar Therapeutics4.0782 of 5 stars$0.63-1.6%$4.50+619.0%-49.3%$116.48M$98.43M-0.75220Positive NewsASMBAssembly Biosciences3.6992 of 5 stars$9.94-0.9%$33.00+232.0%-10.8%$74.58M$28.52M-1.48100Upcoming EarningsNews CoveragePositive NewsCPIXCumberland Pharmaceuticals0.8697 of 5 stars$4.49-5.7%N/A+187.3%$62.72M$37.87M-5.8380Upcoming EarningsShort Interest ↓News CoveragePositive News Related Companies and Tools Related Companies Zoetis Competitors Corcept Therapeutics Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Nektar Therapeutics Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPRX) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.